Review article · 2021 · Open access

Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability

Yitian Zhou, Volker Martin Lauschke

Clinical Pharmacology & Therapeutics, 110(3), 626–636 · Published 10 June 2021 · DOI 10.1002/cpt.2289

Open full textCite this paper

In brief

“Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability” is a 2021 review article by Yitian Zhou and Volker Martin Lauschke, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 39 citations as of 21 November 2026, which puts it in the top 4% of works published in 2021 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Clinical Pharmacology & Therapeutics.

Citations
39
Most cited in
2024 (9)
Field-weighted impact
0.92
References
101
Authors
2

Abstract

Interindividual differences in drug response are a common concern in both drug development and across layers of care. While genetics clearly influences drug response and toxicity of many drugs, a substantial fraction of the heritable pharmacological and toxicological variability remains unexplained by known genetic polymorphisms. In recent years, population-scale sequencing projects have unveiled tens of thousands of coding and noncoding pharmacogenetic variants with unclear functional effects that might explain at least part of this missing heritability. However, translating these personalized variant signatures into drug response predictions and actionable advice remains challenging and constitutes one of the most important frontiers of contemporary pharmacogenomics. Conventional prediction methods are primarily based on evolutionary conservation, which drastically reduces their predictive accuracy when applied to poorly conserved pharmacogenes. Here, we review the current state-of-the-art of computational variant effect predictors across variant classes and critically discuss their utility for pharmacogenomics. Besides missense variants, we discuss recent progress in the evaluation of synonymous, splice, and noncoding variations. Furthermore, we discuss emerging possibilities to assess haplotypes and structural variations. We advocate for the development of algorithms trained on pharmacogenomic instead of pathogenic data sets to improve the predictive accuracy in order to facilitate the utilization of next-generation sequencing data for personalized clinical decision support and precision pharmacogenomics.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhou, Y., & Lauschke, V. M. (2021). Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability. Clinical Pharmacology & Therapeutics, 110(3), 626–636. https://doi.org/10.1002/cpt.2289

MLA 9

Zhou, Yitian, and Volker Martin Lauschke. “Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability.” Clinical Pharmacology & Therapeutics, vol. 110, no. 3, 2021, pp. 626–636. https://doi.org/10.1002/cpt.2289.

Chicago

Zhou, Yitian and Volker Martin Lauschke. 2021. “Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability.” Clinical Pharmacology & Therapeutics 110 (3): 626–636. https://doi.org/10.1002/cpt.2289.

Harvard

Zhou, Y. and Lauschke, V. M. (2021) ‘Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability’, Clinical Pharmacology & Therapeutics, 110(3), pp. 626–636. doi:10.1002/cpt.2289.

IEEE

Y. Zhou and V. M. Lauschke, “Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability,” Clinical Pharmacology & Therapeutics, vol. 110, no. 3, pp. 626–636, 2021, doi: 10.1002/cpt.2289.

BibTeX

@article{zhou2021computational,
  title     = {{Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability}},
  author    = {Zhou, Yitian and Lauschke, Volker Martin},
  journal   = {Clinical Pharmacology \& Therapeutics},
  year      = {2021},
  volume    = {110},
  number    = {3},
  pages     = {626--636},
  doi       = {10.1002/cpt.2289},
  url       = {https://doi.org/10.1002/cpt.2289}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202144
202288
202366
202499
202555
202677

Its field-weighted citation impact is 0.92: it has been cited 0.92 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • pharmacogenomics
  • variant effect prediction
  • non-coding variants
  • rare variants
  • missing heritability
  • drug response prediction
  • synonymous mutations
  • splice variants

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Zhou, Y., & Lauschke, V. M. (2021). Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability. Clinical Pharmacology & Therapeutics, 110(3), 626–636. https://doi.org/10.1002/cpt.2289

How many times has this paper been cited?

39 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the full text from this page.

Who wrote this paper?

Yitian Zhou, Volker Martin Lauschke.

What is the DOI of this paper?

10.1002/cpt.2289, permanently at https://doi.org/10.1002/cpt.2289. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.